<?xml version="1.0" encoding="UTF-8"?>
<p>Eighteen 4-week-old healthy piglets were randomly divided into four groups, including negative control (
 <italic>n</italic> = 3), unvaccinated group (
 <italic>n</italic> = 5), Bartha-K61 group (
 <italic>n</italic> = 5) and Bartha-gCD
 <sub>
  <italic>HB</italic>
 </sub>
 <sub>1201</sub> group (
 <italic>n</italic> = 5). Piglets in the vaccinated group were inoculated via intramuscular (i.m) route with 2 Ã— 10
 <sup>5</sup> TCID
 <sub>50</sub> of either Bartha-K61 or Bartha-gCD
 <sub>
  <italic>HB</italic>
 </sub>
 <sub>1201</sub>, and piglets in unvaccinated group and negative control group were received 2 mL DMEM medium, respectively. Following immunization, the rectal temperature and clinical symptoms were recorded daily. Serum samples were collected weekly to monitor PRV gB-specific and gE-specific antibody responses. At 28 dpi, all pigs were challenged intranasally (i.n) with PRV HB1201 at a dose of 2 mL 10
 <sup>7</sup> TCID
 <sub>50</sub> except for negative control group. After challenge, the clinical signs of disease and rectal temperature were recorded and scored daily. A detailed scoring system is summarized in 
 <xref ref-type="supplementary-material" rid="TS3">Supplementary Table S3</xref>. At 14 dpc, all the survived pigs were euthanized and necropsied, and the tissues were collected for viral load, histopathology, and immunohistochemistry (IHC) analyses.
</p>
